Published on in Vol 12 (2023)
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/46101, first published
.
![Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial](https://asset.jmir.pub/assets/b72b1f0ae783daa1ab8adf8b172735f8.png 480w,https://asset.jmir.pub/assets/b72b1f0ae783daa1ab8adf8b172735f8.png 960w,https://asset.jmir.pub/assets/b72b1f0ae783daa1ab8adf8b172735f8.png 1920w,https://asset.jmir.pub/assets/b72b1f0ae783daa1ab8adf8b172735f8.png 2500w)
There are currently no tweets available for this article within the specified range.